Related Experiment Videos
Multiple mechanisms downregulate CDKN1C in human bladder cancer
Michèle J Hoffmann1, Andrea R Florl, Hans-Helge Seifert
1Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf, Germany.
Abstract:
Expression of the imprinted CDKN1C gene at chromosome 11p15.5 encoding the cell cycle inhibitor p57(KIP2) is disturbed in Beckwith-Wiedemann syndrome and in several human cancers by different mechanisms. Many advanced urothelial cancers (TCC) display downregulation of CDKN1C expression. The responsible mechanisms were investigated in TCC cell lines, with cultured normal urothelial cells (UEC) as controls. CDKN1C mRNA expression was diminished in 12/15 TCC lines and p57(KIP2) protein was decreased accordingly. Because CDKN1C is expressed from the maternal allele only, LOH at 11p15.5 represents one mechanism of downregulation. In 3 cell lines, several polymorphic markers flanking CDKN1C were homozygous compatible with this mechanism. Hypermethylation of the CDKN1C promoter, a reported cause of downregulation in other cancers, was detected by bisulfite sequencing in several cell lines and appeared associated with downregulation in at least one cell line. The methylation inhibitor 5-aza-2'deoxycytidine induced CDKN1C expression in this cell line and others. A third reported mechanism involves a switch of both alleles toward a paternal imprinting pattern, indicated by hypomethylation of a differentially methylated region (DMR) in the imprinting center (IC2). This hypomethylation was detected in most TCC lines, and was associated with re-expression of the non-coding LIT1 RNA and with downregulation of CDKN1C in several. Thus, CDKN1C downregulation in TCC seems to occur by several different mechanisms. This finding and the ability of p57(KIP2) to induce senescence in urothelial cells make CDKN1C a good candidate for a tumor suppressor at 11p in TCC.
Insights
Downregulation of the CDKN1C gene (cell cycle inhibitor p57KIP2) is common in advanced urothelial cancers. Multiple mechanisms, including LOH, promoter hypermethylation, and imprinting changes, contribute to its reduced expression.
Area of Science:
- Oncology
- Genetics
- Epigenetics
Background:
- The CDKN1C gene, encoding the cell cycle inhibitor p57KIP2, is imprinted and located at chromosome 11p15.5.
- Disturbed CDKN1C expression is implicated in Beckwith-Wiedemann syndrome and various human cancers.
- Downregulation of CDKN1C is frequently observed in advanced urothelial cancers (TCC).
Purpose of the Study:
- To investigate the mechanisms responsible for CDKN1C downregulation in TCC.
- To compare CDKN1C expression in TCC cell lines with normal urothelial cells (UEC).
Main Methods:
- Analysis of CDKN1C mRNA and p57KIP2 protein expression in TCC cell lines and UEC.
- Investigation of Loss of Heterozygosity (LOH) at 11p15.5 using polymorphic markers.
- Bisulfite sequencing to assess CDKN1C promoter methylation.
- Treatment with the methylation inhibitor 5-aza-2'deoxycytidine.
- Analysis of imprinting center 2 (IC2) differentially methylated regions (DMRs) and LIT1 RNA expression.
Main Results:
- CDKN1C mRNA and p57KIP2 protein were diminished in 12/15 TCC lines.
- LOH at 11p15.5 was identified in 3 cell lines.
- CDKN1C promoter hypermethylation was detected in several TCC lines, correlating with downregulation in at least one.
- 5-aza-2'deoxycytidine treatment induced CDKN1C expression.
- IC2 hypomethylation, associated with LIT1 re-expression, was found in most TCC lines, correlating with CDKN1C downregulation in several.
Conclusions:
- CDKN1C downregulation in TCC occurs through multiple distinct mechanisms.
- These mechanisms include LOH, promoter hypermethylation, and altered imprinting.
- Given its tumor suppressor potential (p57KIP2 induces senescence), CDKN1C is a promising candidate for 11p tumor suppression in TCC.
Related Concept Videos
Inhibition of Cdk Activity
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation